Tesamorelin ���景与作用机制 — Reference Sheet

By Editorial Desk · published 2026-02-06 · last reviewed 2026-03-30 · Blog

GHRH analog raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2026-03-30. Anything still debated is marked as such rather than presented as settled.

tesamorelin 背景与作用机制

研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。

tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。

Tesamorelin Background and Mechanism

A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.

Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.

Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.

Tesamorelin at a glance

Background and Clinical Development

Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.

A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.

Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.

Related pages on this site

• Scalable archive
• Smart report
• Simple analysis
• Practical review
• Quality playbook
• Standard briefing
• Smart notes
• Connected toolkit

Identity and Development Background

Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.

Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.

Background and Clinical Profile

Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.

After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.

Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.

Reference notes

== See also == Anorectic Eating disorder Fasting Food aversion (disambiguation) Ghrelin Gluttony Hunger strike Hypoglycemia Polyphagia Postprandial somnolence Satiety value Specific appetite Starvation Stomach rumble Taste aversion (disambiguation) Thirst Famine Prader–Willi syndrome

=== Hydrodynamic chromatography === Hydrodynamic chromatography (HDC) is derived from the observed phenomenon that large droplets move faster than small ones. In a column, this happens because the center of mass of larger droplets is prevented from being as close to the sides of the column as smaller droplets because of their larger overall size. Larger droplets will elute first from the middle of the column while smaller droplets stick to the sides of the column and elute last. This form of chromatography is useful for separating analytes by molar mass (or molecular mass), size, shape, and structure when used in conjunction with light scattering detectors, viscometers, and refractometers. The two main types of HDC are open tube and packed column. Open tube offers rapid separation times for small particles, whereas packed column HDC can increase resolution and is better suited for particles with an average molecular mass larger than

== External links == Proprotein+Convertase+1 at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Overview of all the structural information available in the PDB for UniProt: P63239 (Mouse Neuroendocrine convertase 1) at the PDBe-KB.

is called as the Stokes hypothesis. The validity of Stokes hypothesis can be demonstrated for monoatomic gas both experimentally and from the kinetic theory; for other gases and liquids, Stokes hypothesis is generally incorrect. With the Stokes hypothesis, the Navier–Stokes equations become

=== Cancer === Water-soluble polymer shells are being created to deliver a protein, apoptin, into cancer cells. The protein goes into the nucleus of the cancer cells while leaving healthy cells alone, unlike other conventional therapies as gene therapies and chemotherapy. The capsules are 100 nm in size. Active targeting of cancer cells is also being researched. Through active targeting, the nanocapsules form ligands that bind to malignant cells for cell delivery. This method is especially beneficial for those drugs that are not as permeable through the cell membrane, and where tissues are diseased, the nanoparticles are able to bond easier with the malignant cells.

Sources: en.wikipedia.org

Notes from published material

Marrow stole parts from bicycles and assembled "three or four weird-looking, brightly-painted bikes" from the parts; his father either did not notice or never acknowledged this. When Marrow was 13 years old, Solomon also died of a heart attack. Following his father's death, the orphaned Marrow briefly lived with a nearby aunt, then was sent to live with his other aunt and her husband in View Park-Windsor Hills, an upper middle-class Black neighborhood in South Los Angeles. While his cousin Earl was preparing to leave for college, Marrow shared a bedroom with him. Earl was a fan of rock music and listened only to the local rock radio stations; sharing a room with him sparked Marrow's interest in heavy metal music.

=== Block copolymers === Block copolymers comprise two or more homopolymer subunits linked by covalent bonds. The union of the homopolymer subunits may require an intermediate non-repeating subunit, known as a junction block. Diblock copolymers have two distinct blocks; triblock copolymers have three. Technically, a block is a portion of a macromolecule, comprising many units, that has at least one feature which is not present in the adjacent portions. A possible sequence of repeat units A and B in a triblock copolymer might be ~A-A-A-A-A-A-A-B-B-B-B-B-B-B-A-A-A-A-A~.

=== Cancer === Many human oncogenic viruses have been identified. For instance, HHV-8 is linked to Kaposi's sarcoma, the Epstein–Barr virus to Burkitt's lymphoma, and HPV to cervical cancer. In fact, the World Health Organization estimated (2002) that 17.8% of human cancers were caused by infection. The typical methods whereby viruses initiate oncogenesis involve suppressing the host's immune system, causing inflammation, or altering genes. HHV-6 has been detected in lymphomas, leukemias, cervical cancers, and brain tumors. Various medulloblastoma cell lines as well as the cells of other brain tumors have been demonstrated to express the CD46 receptor. Viral DNA has also been identified in many other non-pathological brain tissues, but the levels are lower. The human P53 protein functions as a tumor suppressor. Individuals who do not properly produce this protein experience a higher incidence of cancer, a phenomenon known as Li-Fraumeni syndrome. One of HHV-6's gene products, the U14 protein, binds P53 and incorporates it into virions. Another gene product, the ORF-1 protein, can also bind and inactivate P53. Cells expressing the ORF-1 gene have even been shown to produce fibrosarcomas when injected into mice. Another product of HHV-6, the immediate early protein U95, has been shown to bind nuclear factor-kappa B. Deregulation of this factor is associated with cancer.

In the 2021 Census of Population conducted by Statistics Canada, the census districts within the former city had a population of 629,941 living in 218,928 of its 228,939 total private dwellings, a change of −0.3% from its 2016 population of 632,098. With a land area of 187.70 square kilometres (72.47 sq mi), it had a population density of 3,356.1 people/km2 (8,692 people/sq mi) in 2021. The majority of the district's population is between 25 and 64 years old. 52% fell into that "working age" during the last major survey, which also found 21% of Scarborough's population was 14 years old or younger, 15% were between 15 and 24, while senior citizens aged 65+ made up the remaining 12%. Like the rest of Canada, the population is aging. It is projected that close to 30% of Scarborough residents will be senior citizens by 2041. Scarborough has a large number of retirement communities, which attracts more seniors to the area creating a situation where the two largest age demographics in Scarborough will be over 55 and under 25.

Sources: en.wikipedia.org

Frequently asked questions